Immune checkpoint inhibitors for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors for hepatocellular carcinoma

Published:2019-07-10 Issue:19 Volume:125 Page:3312-3319
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

El Dika Imane¹²,Khalil Danny N.¹²³⁴,Abou‐Alfa Ghassan K.¹²^ORCID

Affiliation:

1. Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center New York New York

2. Department of Medicine Weill Cornell Medical College New York New York

3. Ludwig Collaborative and Swim Across America Laboratory Memorial Sloan Kettering Cancer Center New York New York

4. Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32076

Reference54 articles.

1. The evolving epidemiology of hepatocellular carcinoma: a global perspective

2. HCV eradication induced by direct‐acting antiviral agents reduces the risk of hepatocellular carcinoma [published online September 5, 2017];Ioannou GN;J Hepatol

3. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

4. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

5. Epidemiology of Hepatocellular Carcinoma

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of mitochondrial phosphoenolpyruvate carboxykinase with prognosis and immune regulation in hepatocellular carcinoma;Scientific Reports;2024-06-18

2. Single‐cell profiling reveals the metastasis‐associated immune signature of hepatocellular carcinoma;Immunity, Inflammation and Disease;2024-05

3. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma;Cancer Research Communications;2024-03-07

4. Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review;Journal of Cancer Research and Clinical Oncology;2024-02-06

5. LOXL4 Shuttled by Tumor Cells–derived Extracellular Vesicles Promotes Immune Escape in Hepatocellular Carcinoma by Activating the STAT1/PD-L1 Axis;Journal of Immunotherapy;2023-12-04